Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/08/22
End: 11/30/24
Due: 11/30/25
Phase: N/A
Priority: Normal
Start: 08/05/19
End: 08/30/25
Due: 08/30/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer | NCT05501769 | Arvinas Estrogen Receptor, Inc. | user2@example.com | None | 2022-09-08 | 2024-11-30 | 2025-11-30 | - | - | 2025-07-14 |
| A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer | NCT04072952 | Arvinas Estrogen Receptor, Inc. | user2@example.com | None | 2019-08-05 | 2025-08-30 | 2026-08-30 | - | - | 2025-07-14 |